Health AI Central
Share:
Peer-Reviewed Publication
J Antimicrob Chemother2020;75(9):2708-2710.September 1, 2020Letter

Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19.

Nathan Peiffer-Smadja1,2, François-Xavier Lescure1,3, Erwan Sallard4, Philippe Ravaud5, Bruno Vegreville6, Jean-David Zeitoun5,6
1Université de Paris, IAME, INSERM, F-75018 Paris, France.
2National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
3Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018 Paris, France.
4École normale supérieure de Paris, 45 rue d'Ulm, 75005 Paris, France.
5U1153, Epidemiology and Biostatistics Sorbonne, Paris Cite Research Center (CRESS), Methods of therapeutic evaluation of chronic diseases team (METHODS), INSERM, Université Paris Descartes, Paris, Île-de-France, France.
6Inato, Paris, France.
PubMed PMC DOI PDF

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.